1-4 of 4
Changpu Yu, MD
Close
Sort by
Journal Articles

SGN-CD33A in Combination with Cytarabine or Hypomethylating Agents Demonstrates Enhanced Anti-Leukemic Activity in Preclinical Models of AML

May S.K. Sutherland, PhD, Changpu Yu, MD, Martha Anderson, Kim Emmerton, Weiping Zeng, MD, Megan M. O'Meara, MD, Dana A. Kennedy, PharmD, BCOP, Maureen C. Ryan, PhD, Dennis R. Benjamin, PhD
Journal: Blood
Blood (2014) 124 (21): 3739.
https://doi.org/10.1182/blood.V124.21.3739.3739
Published: 2014
Journal Articles

SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

May S.K. Sutherland, PhD, Roland B. Walter, MD, PhD, Scott C. Jeffrey, PhD, Patrick J. Burke, PhD, Changpu Yu, MD, Kimberly H. Harrington, BS, Ivan Stone, BS, Maureen C. Ryan, PhD, Django Sussman, PhD, Weiping Zeng, MD, Dennis R. Benjamin, PhD, Irwin D. Bernstein, MD, Peter D. Senter, PhD, Jonathan G. Drachman, MD, Julie A. McEarchern, PhD
Journal: Blood
Blood (2012) 120 (21): 3589.
https://doi.org/10.1182/blood.V120.21.3589.3589
Published: 2012
Journal Articles

SGN-33, Lintuzumab, Demonstrates Anti-Leukemic Activity in Preclinical Models of AML.

May S.K. Sutherland, PhD, Changpu Yu, MD, Carol Morris-Tilden, Timothy S. Lewis, PhD, Jamie B. Miyamoto, Julie A. McEarchern, PhD, Ezogelin Oflazoglu, PhD, Hanspeter Gerber, PhD, Eric L. Sievers, MD, Iqbal S. Grewal, PhD, Che-Leung Law, PhD
Journal: Blood
Blood (2007) 110 (11): 919.
https://doi.org/10.1182/blood.V110.11.919.919
Published: 2007
Journal Articles

SGN-33 Modulates Cytokine and Chemokine Production by Activated Monocytes and Macrophages.

May S.K. Sutherland, PhD, Timothy S. Lewis, PhD, Changpu Yu, MD, Julie A. McEarchern, PhD, Jonathan G. Drachman, MD, Eric L. Sievers, MD, Iqbal S. Grewal, PhD, Che-Leung Law, PhD
Journal: Blood
Blood (2006) 108 (11): 1995.
https://doi.org/10.1182/blood.V108.11.1995.1995
Published: 2006